Working… Menu
Trial record 1 of 1 for:    keynote 158
Previous Study | Return to List | Next Study

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02628067
Recruitment Status : Recruiting
First Posted : December 11, 2015
Last Update Posted : March 3, 2021
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 18, 2026
Estimated Study Completion Date : June 18, 2026
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):